• E-ISSN 2636-7688
  • Call Us: +90 422 341 06 60 / 1224
  • Email Us: dergi@inonu.edu.tr

Formerly Journal of Turgut Ozal Medical Center - ISSN 1300-1744

  • Annals of Medical Research



    Annals of Medical Research International Monthly Published Medical Journal

  • Annals of Medical Research

    In publication or citation search, the name similarities of the authors, typographical errors and institutional changes can cause confusion. To prevent this, researchers need to obtain a descriptive ID. ORCID (Open Researcher and Contributor ID) is a researcher-specific international URI with a 16-digit number. You can register for free for individual ORCID at http://orcid.org. Please indicate the ORCID number of all authors when submitting your article.

  • Annals of Medical Research


    Annals of Medical Research indexed in TÜBİTAK/ULAKBİM Tıp Veri Tabanı

  • Annals of Medical Research


    Annals of Medical Research indexed in

  • Annals of Medical Research
  • Annals of Medical Research
  • Annals of Medical Research
  • Annals of Medical Research

Dear readers,

Our journal is the official publication of Inonu University Medical Faculty and published uninterruptedly for 25 years. It was first published as the name of Inonu University Medical Journal and later as Journal of Turgut Ozal Medical Center. During its publication period, the journal accepted Turkish or English articles for publication.

Abstracting in an international index is just a paramount objective in the 25th year of the journal. Because of this goal, it was necessary to make a decision both in terms of journal name and publication language. It was important in this respect that the name of a general medical journal should be related to medicine again and it should be in English. For these reasons, the name of the journal was switched to Annals of Medical Research and its publication language is changed to in English. The logo of the journal was chosen as an apricot, which is the symbol of our city Malatya, the world capital of apricot. I hope the journal succeeds with its new name. Annals of Medical Research is published monthly.

Editor-in-Chief

 

Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study (p.29-33)

Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study (p.29-33)

Halil Taskaynatan1, Yuksel Kucukzeybek2, Yasar Yildiz2, Tarik Salman2, Utku Oflazoglu2, Umut Varol3, Ahmet Alacacioglu2, Seray Saray2, Ozlem Ozdemir4, Mustafa Oktay Tarhan5
1Kahramanmaras Necip Fazil City Hospital, Clinic of Medical Oncology, Kahramanmaras, Turkey
2Izmir Katip Celebi University, Ataturk Training and Research Hospital, Department of Medical Oncology, Izmir, Turkey
3Izmir Demokrasi University, Faculty of Medicine, Department of Medical Oncology, Izmir, Turkey
4Izmir Bozyaka Training and Research Hospital, Department of Medical Oncology, Izmir, Turkey
5Izmir Dokuz Eylul University, Faculty of Medicine, Department of Medical Oncology, Izmir, Turkey

Copyright © 2020 by authors and Annals of Medical Research Publishing Inc.

Abstract

Aim: Oral etoposide dosage is roughly 50-100 mg/m2 on days 1 to 21 every 28 days. However, dosage of 50 mg/day oral etoposide for five days a week is not well published. The present study, aimed to evaluate the efficacy and toxicity profile of low dose oral etoposide regimen (50 mg/day on days 1 to 5 every week) in platinum-resistant epithelial ovarian cancer (EOC).
Material and Methods: This study retrospectively evaluates patients with pathologically confirmed platinum-resistant EOC who were unable to tolerate the standard oral etoposide regimen and were on low dose (d1-5/7) oral etoposide regimen in third line or beyond within the period between 2006 and 2014.
Results: The overall response rate among 33 EOC patients was 15.1% while clinical benefit rate was 42.4% (stable disease in 27.3% and partial response in 15.1%). Median progression-free survival was 4 months (95% confidence interval [CI], 2.8–5.1 months) and median overall survival was 12 months (95% CI, 8.8–15.1 months).
Conclusion: We concluded that low dose oral etoposide (50 mg/day, on days 1 to 5 every week) was effective and well tolerated for platinum-resistant EOC.

Keywords: Epithelial ovarian cancer; oral etoposide; recurrence

 

 

DOWNLOAD
doi: 10.5455/annalsmedres.2019.12.862

DownloadXML


Contact us

+90 422 341 06 60 / 1224 - University

+90 422 341 06 60 Department


Location

Inonu University Faculty of Medicine

Malatya, 44069

Turkey


Send us email

dergi@inonu.edu.tr

dergi@inonu.edu.tr


demo

Annals of Medical Research is the scientific official journal of the Inonu University Faculty of Medicine. It is published monthly. The essential aim of the Annals of Medical Research is to publish scientifically high quality clinical and experimental research articles on fields of medicine which can contribute to the literature data. In addition, review articles, case reports, editorials, letters to the editors and manuscripts on publication ethics and medical history, which can contribute to the education and practices of physicians and health sector professionals within the scope of the journal’s target audience and which can increase the level of scientific communication between the authors and readers, are included in the scope of the journal.

 

Recent News

Links

Web Traffic

Today229
Yesterday912
This week2020
This month21535
Total21535

2020-09-30

Certificate of General Impact Factor

Email Newsletter

Sign up for the latest Inonu University Our new article, updates....